Eli Lilly and Company announced major findings from the seven-year monarchE trial. Their CDK4/6 inhibitor, Verzenio® (abemaciclib), is the first in its class to demonstrate a statistically significant overall survival benefit for patients with HR+, HER2-, high-risk early breast cancer when added to endocrine therapy.
A landmark study by Ohio State scientists reveals the underlying mechanism of cancer immunotherapy failure: a fatal “proteotoxic shock” or protein quality control collapse (TexPSR) in T-cells. This newly identified stress pathway overwhelms immune cells with misfolded proteins, disabling their tumor-fighting function. Crucially, blocking the TexPSR pathway in preclinical models restored T-cell function and made immunotherapy markedly more effective, offering an entirely new target for cancer treatment development.
AbbVie reaches a key milestone by submitting a Biologics License Application (BLA) to the FDA for Pivekimab sunirine (PVEK), an investigational Antibody-Drug Conjugate (ADC) designed to treat the rare and aggressive blood cancer, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Roche’s Phase III evERA study for the investigational drug giredestrant has delivered positive results, showing a significant improvement in progression-free survival for patients with advanced ER-positive breast cancer. The all-oral combination therapy, which was well-tolerated, offers a new, promising treatment option for individuals whose disease has progressed after previous treatments.
AstraZeneca‘s supplemental biologics license application (sBLA) for Imfinzi (durvalumab) has been approved and given priority review in the U.S. FDA for the treatment of patients with [Read More…]
Pfizer and Astellas report groundbreaking Phase 3 EMBARK trial results showing XTANDI® (enzalutamide) plus leuprolide significantly improves overall survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence. This marks the first time an androgen receptor inhibitor-based therapy has shown a definitive survival benefit in this specific patient population, offering new hope for extending lives through early and effective treatment.
Amgen has announced positive topline results from the Phase 3 FIGHT trial evaluating bemarituzumab in combination with chemotherapy for advanced gastric and gastroesophageal junction (GEJ) cancer.
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
The VENTANA MET (SP44) RxDx Assay detects the MET, or c-Met, protein, which is overexpressed in about 25% of advanced NSQ-NSCLC patients with EGFR wild-type.
Immunotherapies and other cancer treatments don’t work well on “cold” tumors, also known as immunological deserts, because they usually have few T cells.
